uMotif has entered a collaboration with ClinOne to combine electronic clinical outcome assessments (eCOA) / patient reported outcomes (ePRO) and electronic informed consent (eConsent) technology to boost the participant experience and endpoint data quality in global clinical trials.

Through the alliance, the companies will offer the international life sciences industry a single, integrated solution supported by an intuitive user experience that delivers superior eCOA and eConsent technology.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Extensibility and intuitive user experiences are the core of the platforms developed by the companies. 

They can enable complete decentralised clinical trials (DCT), standard site-based trials and hybrid designs of any scale or treatment area complexity when used together.

The integrated offering is said to be affordable, quick to install and simple for use by subjects on their own familiar mobile devices.

See Also:

eCOA / ePRO and engagement platform of uMotif boosts subject experience while enhancing dependability of patient-reported and site-based endpoint data utilised for approval decisions on new therapies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

uMotif CEO Steve Rosenberg said: “It is encouraging and refreshing to see so many sponsors and CROs adopt patient-first technologies like eCOA, ePRO and eConsent, but too often they are frustrated by disjointed solutions that place a high burden on users and limit effectiveness. 

“Together, uMotif and ClinOne are setting out to directly address these pain points with a seamless and comprehensive solution that trial participants actually want to use. 

“In this way, we will add immediate value to increase data quality and reduce risk while improving convenience and comfort for everyone involved with the trial.”

eConsent on the adaptive experience platform of ClinOne lowers the likelihood of consent-linked errors and allows better informed participation decisions. 

Together they offer a smooth participant experience across a wide range of therapeutic areas and trial designs.